65,437 trials
Relapsing-Remitting Multiple Sclerosis
Primary: Annualized Relapse Rate — 0.401; 0.224; 0.198; 0.286 Relapses Per Year
Gastroesophageal Reflux Disease
Primary: To Evaluate the Incidence of All Adverse Events at Various Time Points. — 29 participants
Socket Designs of Transfemoral Amputees.
Primary: Gait
Prostate Cancer
Primary: Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With Degarelix — 90.0 percentage of participants
Melanoma
Primary: Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator for Participants Who Had…
Lymphoma
Primary: Toxicity — 1; 8 participants
Respiratory Failure
Primary: Scores in Pre and Post-test, Number of Participants Successfully Completing the Overall Performance Simulated Scenario(OSCE). — 6.6; 6.5; 8.6; 8.4 units on a scale
Sexual Dysfunction, Physiological
Primary: Persistently Elevated Serum Estradiol Level Outside the Post-menopausal Range — 0; 4 participants
Coronary Disease · Verapamil Toxicity
Primary: Rate of Access Site Conversions — 2; 5 participants — p=0.28
Waldenstrom's Macroglobulinemia · Lymphoplasmacytic Lymphoma
Primary: Objective Response Rate — 1; 15; 2; 7 participants
Osteoblast · Adipocytes · Bone Density
Primary: Percent Change in Number of Osteoblast and Adipocyte Colony Forming Units Cultured From Bone Marrow Stem Cells Harvested 6 Months After Treatment With Study Drug…
Acute Coronary Syndrome · Myocardial Infarction · Myocardial Ischemia
Primary: The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke — 7.4; 6.1; 6.1 Percentage of patients — p=0.020
Relapsing-Remitting Multiple Sclerosis
Primary: Proportion of Subjects Relapsed — 0.461; 0.270; 0.260 Proportion of subjects,confirmed relapse
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.2; 1.5; 0.9 events per month
Gastroesophageal Reflux Disease (GERD)
Primary: Number of Participants Discontinuing Due to Symptom Worsening in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint) — 1; 6; 8; 12 Participants